Pediatric gray zone lymphoma according to the 2022 WHO classification: An Italian cohort study

Pediatr Blood Cancer. 2023 May 30:e30481. doi: 10.1002/pbc.30481. Online ahead of print.

Abstract

Background: The 2022 World Health Organization (WHO) classification redefines the concept of gray zone lymphoma (GZL), restricting it in practice to cases of mediastinal/thymic origin (mediastinal gray zone lymphoma, MGZL) with overlapping features between primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma (CHL). Cases with histological characteristics of GZL but occurring without mediastinal involvement are better classified as diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS), with few exceptions.

Procedure: We collected clinical and pathological data about all Italian pediatric patients diagnosed with GZL over a 20-year period.

Results: We identified only four cases of bona fide MGZL. All patients were adolescent and presented with a mediastinal disease, always associated with other nodal involvement. B symptoms and increased levels of both erythrocyte sedimentation rate (ESR) and lactate dehydrogenase (LDH) were observed. Only two patients achieved a first complete remission, suggesting a more aggressive clinical behavior than either PMBCL or CHL.

Conclusion: Prospective studies evaluating prognostic factors and establishing the most effective first-line therapy for MGZL are highly needed.

Keywords: WHO classification; gray zone lymphoma; mediastinum; pediatrics.